Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

ZORBTIVE™ (somatropin)

GPI CODING:

30100020102132

DESCRIPTION:

ZORBTIVE is indicated for the treatment short bowel syndrome in patients receiving specialized nutritional support. ZORBTIVE therapy should be used in conjunction with optimal management of short bowel syndrome. Short-bowel syndrome is a malabsorptive disorder that may be congenital (intestinal atresia) or acquired (due to surgical resection). The role of GH therapy is to enhance bowel adaptation and increase the chances of liberating patients from requiring parenteral nutrition. GH has been shown to heighten the transmucosal transport of water, electrolytes, and nutrients via interaction with GH and IGF-1 receptors on intestinal mucosa. ZORBTIVE for more than 4 weeks has not been adequately studied.

APPROVAL DURATION:

Approval duration: 4 weeks. Additional authorizations not provided.

CRITERIA FOR ZORBTIVE

I. Patient has a diagnosis of short bowel syndrome **AND**
II. Patient is receiving specialized nutritional support (i.e. parenteral nutrition)